Daewoong pharmaceutical Co.,Ltd

KSE 069620.KS

Daewoong pharmaceutical Co.,Ltd Gross Profit for the year ending December 31, 2023: USD 527.70 M

Daewoong pharmaceutical Co.,Ltd Gross Profit is USD 527.70 M for the year ending December 31, 2023, a 4.54% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Daewoong pharmaceutical Co.,Ltd Gross Profit for the year ending December 31, 2022 was USD 504.78 M, a 10.71% change year over year.
Daewoong pharmaceutical Co.,Ltd Gross Profit for the year ending December 31, 2021 was USD 455.95 M, a 11.13% change year over year.
Daewoong pharmaceutical Co.,Ltd Gross Profit for the year ending December 31, 2020 was USD 410.29 M, a -0.48% change year over year.
Daewoong pharmaceutical Co.,Ltd Gross Profit for the year ending December 31, 2019 was USD 412.29 M, a 12.50% change year over year.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

KSE: 069620.KS

Daewoong pharmaceutical Co.,Ltd

CEO	Mr. Chang-Jae Lee
IPO Date	Sept. 29, 2005
Location	South Korea
Headquarters	12, Bongeunsa-ro 114-gil
Employees	1,710
Sector	Health Care
Industries Pharmaceuticals

Description

Daewoong Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years